Scalp

Pioneering Eco Haircare brand Rhyme & Reason Upgrade their High Performance Regimes with bespoke Rosemary Scalp Serum

Retrieved on: 
Thursday, March 21, 2024
Giant, CVS, Rite Aid, Serum, Social media, Kroger, Love, Scalp, Multimedia, Soil, Hydrate, Giant Eagle, Rhyme & Reason, Cosmetics

Rhyme & Reason's high-performance formulations now come with Rosemary scalp serum, to make certain that both hair and scalp are receiving the love and care they need.

Key Points: 
  • Rhyme & Reason's high-performance formulations now come with Rosemary scalp serum, to make certain that both hair and scalp are receiving the love and care they need.
  • In a recent survey conducted by Rhyme & Reason, the brand determined that 75% of US consumers felt that a healthy scalp is just as important as healthy hair**.
  • And in response, Rhyme & Reason have now made caring for both your hair & scalp super easy with shampoos & conditioners enriched with Rosemary scalp serum - proven to leave hair and scalp feeling nourished & hydrated.
  • The rosemary scalp serum does a great job at both nourishing and hydrating the scalp.

Research case series presents food as medicine as a potential treatment for lupus and other autoimmune diseases

Retrieved on: 
Tuesday, March 19, 2024
Arthralgia, Series, Brain, Xerostomia, Face, Malar rash, Kidney, Lupus, Photosensitivity, Pleurisy, Inflammation, Patient, Raw foodism, Tissue, Research, History, Grit, Hair loss, Food, Seed, MD, Quality of life, Woman, Arthritis, Chronic pain, Skin, Water, Sunlight, Scalp, Immune system, Grain boundary strengthening, Frontiers, RRP, Fatigue, Swelling, Flax, Autoimmune disease, Nut, Medicine, Dietary supplement

ST. LOUIS, March 19, 2024 /PRNewswire-PRWeb/ -- A new research case series published in Frontiers in Nutrition presents food as medicine as a potential treatment for autoimmune diseases, describing three patients with chronic autoimmune disease who showed remarkable improvement after following a predominantly raw dietary pattern high in cruciferous vegetables and omega 3 fatty acids.

Key Points: 
  • ST. LOUIS, March 19, 2024 /PRNewswire-PRWeb/ -- A new research case series published in Frontiers in Nutrition presents food as medicine as a potential treatment for autoimmune diseases, describing three patients with chronic autoimmune disease who showed remarkable improvement after following a predominantly raw dietary pattern high in cruciferous vegetables and omega 3 fatty acids.
  • All three women reported that nearly all their symptoms of both diseases resolved after just four weeks of making the dietary changes.
  • "My hope is that these cases generate greater recognition, making patients and clinicians aware of food as medicine as a treatment option for systemic lupus erythematosus and Sjögren's syndrome.
  • This case series also reflects the immediate need for more research into dietary changes as a potential treatment strategy for autoimmune disease."

Luvme Hair Launches New Wig Renewal System: Wig Shampoo + Wig Conditioner

Retrieved on: 
Friday, March 15, 2024
Rejuvenation, Life, Longevity, Scalp, Cosmetics

NEW YORK, March 15, 2024 /PRNewswire/ -- Luvme Hair , a leading brand in the human hair wigs industry, has announced the launch of its Wig Renewal System , the first-ever wig-exclusive clean and care system.

Key Points: 
  • NEW YORK, March 15, 2024 /PRNewswire/ -- Luvme Hair , a leading brand in the human hair wigs industry, has announced the launch of its Wig Renewal System , the first-ever wig-exclusive clean and care system.
  • The Wig Renewal Shampoo and The Wig Renewal Conditioner are set to redefine the standard for human hair wig maintenance and wig care.
  • Normal formula shampoos and conditioners designed for scalp-growing hair cannot provide the exact and sufficient supplements for wig hair.
  • Backed by 3 years of meticulous planning and trials, along with 20 years of unparalleled expertise in wig hair, the Wig Renewal System addresses the unique needs of wig wearers.

Celluma Light Therapy Introduces the RESTORE Hair Therapy System

Retrieved on: 
Thursday, March 14, 2024
DHT, Vitamin, Adenosine triphosphate, Serum, Inflammation, Zinc, Hair loss, Glycine, Scalp, ATP, FDA, Microcirculation, Peptide, Cosmetics

TUSTIN, Calif., March 14, 2024 /PRNewswire/ -- BioPhotas, Inc., the makers of Celluma Light Therapy and market leader in therapeutic LED light therapy devices, announced today the launch of the RESTORE Hair Serum, an optimized scalp and hair formulation that complements the award-winning Celluma RESTORE LED device to provide a complete hair-restoration solution.

Key Points: 
  • TUSTIN, Calif., March 14, 2024 /PRNewswire/ -- BioPhotas, Inc., the makers of Celluma Light Therapy and market leader in therapeutic LED light therapy devices, announced today the launch of the RESTORE Hair Serum, an optimized scalp and hair formulation that complements the award-winning Celluma RESTORE LED device to provide a complete hair-restoration solution.
  • "It's an amazingly elegant formulation that is clear and easily absorbed into the scalp so that it can be used daily to maximize the Celluma Light Therapy results."
  • For the growing number of professionals and individuals achieving significant and visible results with the FDA-cleared Celluma RESTORE Light Therapy device for hair restoration, this serum is an ideal complement for use between each light therapy treatment.
  • According to Mr. Cluff, "the Celluma RESTORE light therapy device has been available since receiving FDA-clearance for hair restoration in 2021.

Give Your Wash Day Experience a Brand-New Feel! Haircare Brand African Pride Introduces a Sensory Regimen with Its Newest Collection, Feel It Formula!

Retrieved on: 
Tuesday, March 12, 2024
Mineral oil, Sage oil, Target, Sulfate, Petroleum, Hair loss, Formula, Walmart, Peppermint, Rosemary, Scalp, SRP, Collection, Cosmetics

ATLANTA, March 12, 2024 /PRNewswire/ -- African Pride, the trusted and legacy haircare brand, proudly unveils its latest innovation – the 'Feel It Formula' haircare line. This 4-step collection is meticulously crafted to redefine the 'Wash Day Experience,' offering a sensory regimen that caters to all hair types, chemical, relaxed, or transitioning; restoring dry, damaged hair, and treating irritated scalps #feelthedifference.

Key Points: 
  • This 4-step collection is meticulously crafted to redefine the 'Wash Day Experience,' offering a sensory regimen that caters to all hair types, chemical, relaxed, or transitioning; restoring dry, damaged hair, and treating irritated scalps #feelthedifference.
  • The NEW African Pride 'Feel It Formula' line ignites your senses through stimulating fragrances, invigorating sensations, and nourishing formulas.
  • African Pride Feel It Formula Peppermint, Rosemary & Sage Strengthening Shampoo (SRP $6.99) - Deeply cleanses hair and scalp, removing product build-up without stripping moisture.
  • African Pride Feel It Formula Peppermint, Rosemary & Sage Strengthening Mask (SRP $6.99) - Strengthens and hydrates hair strands from root to tip.

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

Retrieved on: 
Monday, March 4, 2024
Cream, Foam, Doctor of Philosophy, Psoriasis, Randomized controlled trial, MD, Atopic dermatitis, Dermatitis, Itch, AAD, FAAD, Scalp, American Academy

New efficacy and patient-reported outcome data of ZORYVE (roflumilast) topical foam, 0.3%, in seborrheic dermatitis and investigational roflumilast foam in scalp and body psoriasis

Key Points: 
  • New efficacy and patient-reported outcome data of ZORYVE (roflumilast) topical foam, 0.3%, in seborrheic dermatitis and investigational roflumilast foam in scalp and body psoriasis
    WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting, which will take place in San Diego, CA from March 8 - 12, 2024.
  • Among these presentations will be late-breaking clinical data on roflumilast cream 0.05% in patients 2 to 5 years of age with mild to moderate atopic dermatitis from the pivotal INTEGUMENT-PED Phase 3 randomized controlled trial.
  • “Our significant presence at this year’s AAD is a testament to our commitment to bringing meaningful innovation in immuno-dermatology, and building on the body of evidence supporting our topical roflumilast development program.
  • In particular, we are excited to be participating in the late breaking data presentations with new results from INTEGUMENT-PED, as part of our atopic dermatitis clinical program,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer, Arcutis.

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
Janus, Acquisition, Week, Psoriasis, GTN, Research, Health Canada, Investment, Inflammation, FDA, Marketing, Atopic dermatitis, Food, Dermatitis, Growth, Shanda, Patent, JAK1, PDUFA, Pharmacy benefit management, PDE4, Alopecia areata, Food and Drug Administration, Webcast, Half-life, Disease, SLR, Itch, NDA, Prescription, Scalp, Pharmaceutical industry

The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.

Key Points: 
  • The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.
  • Total revenues for the quarter ended December 31, 2023 were $13.5 million compared to $3.0 million for the corresponding period in 2022.
  • Net cash used in operating activities was $56.2 during the fourth quarter and $247.1 million during the full year 2023.
  • Arcutis management will host a conference call and webcast today at 8:30 am ET to discuss the financial results for the quarter and year and provide a business update.

Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in the Journal Cellular Reprogramming

Retrieved on: 
Thursday, February 22, 2024
Research, Genetics, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Ageing, Mouse, KLF4, Notifiable disease, Vivisection, Stem cell, Scalp, Biomarker, OSK, Keratinocyte, Heart, Male, Yamanaka, AAV, DNA methylation, DNA, Vaccine

The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.

Key Points: 
  • The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.
  • While aging cannot be prevented, interventions targeting cellular processes offer potential for mitigating its impact on health and lifespan in the elderly.
  • Rejuvenate Bio's research focuses on partial reprogramming using the Yamanaka factors, specifically OCT4, SOX2, and KLF4 (OSK), to reverse age-related changes.
  • These results may have important implications for the development of partial reprogramming interventions to reverse age-associated diseases in the elderly population.”

Maesa Proudly Presents Inaugural Graduating Class of the #MaesaMagicIncubator

Retrieved on: 
Tuesday, February 20, 2024
General Health, Other Retail, Entrepreneur, Training, Consumer, Mental Health, Other Education, Fashion, Cosmetics, Education, Retail, Women, Health, Woman, Beauty, Multimedia, Entrepreneurship, TPH, Magic, Emerson Group, Thought, CPG, Commerce, Skin, Feedback, Create, Hair removal, House, Motivational speaker, Work, Irritation, Scalp, Face, Management

Maesa, the #1 beauty incubator in mass, is proud to announce the graduation of the inaugural cohort, class of 2024 of the #MaesaMagicIncubator.

Key Points: 
  • Maesa, the #1 beauty incubator in mass, is proud to announce the graduation of the inaugural cohort, class of 2024 of the #MaesaMagicIncubator.
  • “In our 2024 class, we see the will to make magic by delivering products that solve real problems and fulfill unmet consumer needs.
  • Through the #MaesaMagicIncubator, Maesa seeks to address the challenges faced by promising early-stage entrepreneurs who, much like Maesa, are crafting consumer solutions that are disrupting categories and creating magic.
  • By nurturing diverse ideas, Maesa aims to stimulate innovation and foster economic growth, creating a ripple effect of shared success and satisfying unmet consumer needs.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

Retrieved on: 
Saturday, March 9, 2024
Pustulosis palmaris et plantaris, Psoriasis, CPU socket, Aes, Headache, Diarrhea, Amgen, Pain, Pediatrics, DLQI, Skin, Nausea, Vomiting, Queen's University, AMGN, AAD, Safety, University, FRCPC, University of Alberta, PASI, Dermatology Life Quality Index, Patient, PST, Scalp, Ageing, Abdominal pain, Poster, American Academy, Pharmaceutical industry

THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.                                     

Key Points: 
  • These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
  • "These data reflect Amgen's commitment to exploring new ways to treat inflammatory skin disease," said Ponda Motsepe-Ditshego, vice president, Global Medical, at Amgen.
  • Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in patients for up to one year.
  • Findings will be presented as a late-breaking oral presentation on Saturday, March 9 at 9:20 a.m. PST.